MacroGenics
About
What does MacroGenics do?
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for cancer, autoimmune disorders, and infectious diseases. They leverage proprietary technology platforms like DART® and Trident™ to create bispecific and trispecific antibodies that target multiple antigens or cells, aiming to enhance the immune system's ability to fight disease. The company has a pipeline of product candidates and strategic collaborations with…
What is MacroGenics's revenue?
StartupHub estimates MacroGenics's annual revenue at $5.8M (range $782K to $13.4M, 29% confidence), based on comparable companies in the sector.
What is MacroGenics's valuation?
StartupHub estimates MacroGenics's effective valuation at $53.7M (range $33.8M to $81.0M, 10% confidence), based on comparable companies in the sector.
How much funding has MacroGenics raised?
MacroGenics has raised a total of $14M in funding. The most recent round on record is Series A.
Where is MacroGenics headquartered?
MacroGenics is headquartered in Rockville, United States.
When was MacroGenics founded?
MacroGenics was founded in 2000.
What industry does MacroGenics operate in?
MacroGenics operates in Biotech, MedTech, HealthTech, Genomics, Drug Discovery, Clinical Trials.
No comments yet. Be the first to share your take.